Kwality Pharmaceuticals Receives Product Approvals for Biological Product PEGylated-Asparaginase

Kwality Pharmaceuticals Ltd. (KPL) has announced the successful receipt of domestic and export product approvals for the manufacturing and sale of its biological product, PEGylated-Asparaginase. This marks a significant milestone for the company, being its first product from the biologics portfolio to be commercialized in both domestic and export markets. PEGylated-Asparaginase is an E. coli-derived enzyme primarily used in the treatment of acute lymphoblastic leukemia (ALL). The PEGylation process enhances the stability of the molecule and reduces the risk of allergic reactions, thereby improving patient outcomes and treatment efficacy. Kwality is also in discussions with leading domestic B2B companies to offer PEGylated-Asparaginase on a CDMO basis, aiming to leverage their manufacturing expertise and enhance patient access across various regions.